Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and oxaliplatin with radiation for advanced rectal cancer, plus cetuximab for KRAS wild-type
2009-010976-94Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab, capecitabine and oxaliplatin in rectal cancer and anal cancer (2 arms), sponsored by Herlev Hospital. Primary endpoint: Tumor response rate. Started Jun 2009; status: completed.
02
Drugs
cetuximabcapecitabineoxaliplatin
03
Conditions
rectal canceranal cancer
Beyond the preview
Go deeper on 2009-010976-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010976-94.